BioTheranostics racks up $32 mln
San Diego-based BioTheranostics, a provider of molecular diagnostic tests for cancer, has raised $32 million in funding. MVM Life Science Partners led the round with participation from Canepa Advanced Healthcare Fund and HealthQuest Capital. As a result of the transaction, BioTheranostics will spin out from BioMérieux, which will retain a minority stake.
21 January 2016•2 mins read
